IP Library › Granted Patent US 10,561,805
Granted Patent B2
US 10,561,805 · App. 15/517,693 · Granted Feb 18, 2020

Methods of treating RSV infections

Inventors: Koen Allosery (Ostend, BE); Erik Depla (Destelbergen, BE); Martin Huber (Gauting, DE); Tobias Kolb (Gauting, DE); Bernhard Müllinger (Gauting, DE); Massimiliano Germani (Geel, BE); Juliane Schick (Gauting, DE); Maria-Laura Sargentini (Brussels, BE)
Assignees: ABLYNX N.V.; VECTURA GMBH
A61M15/002A61K9/0078A61K39/42A61K45/06A61M15/009A61M15/0021A61M15/025C07K16/10C07K16/1027A61K2039/505A61K2039/54A61K2039/545A61M2202/025A61M2202/0208A61M2202/0266A61M2206/11A61M2240/00C07K2317/56C07K2317/565C07K2317/567C07K2317/569C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,805
App. No.
15/517,693
Granted
Feb 18, 2020
Kind
B2
Abstract

Methods are provided for the treatment of RSV infections in young children. More specifically, methods are provided wherein polypeptides that bind F protein of hRSV and that neutralize RSV infection are administered to the lungs of young children at specific dose regimens.

Claims (11)

1. A method for treating a respiratory syncytial virus (RSV) infection in a young child, the method comprising the following step:

administering to a subject a polypeptide that binds a protein of human RSV (hRSV), wherein the protein is glycoprotein F (F-protein), wherein the polypeptide has the amino acid sequence of SEQ ID NO: 71, wherein the polypeptide is administered by inhalation with a vibrating mesh nebulizer at a deposited dose of 0.020-0.040 mg/kg daily and wherein the subject is a young child.

2. The method of claim 1 , wherein the polypeptide is administered at an inhaled dose of 0.20-0.40 mg/kg daily.

3. The method of claim 1 , wherein the polypeptide is administered at a nominal dose of 1.00-2.00 mg/kg daily.

4. The method of claim 1 , wherein the step of administering is performed daily for 2 to 5 consecutive days.

5. The method of claim 1 , wherein the step of administering is performed daily for 3 consecutive days.

6. The method of claim 1 , wherein the young child is less than 2 years old.

7. The method of claim 1 , wherein the step of administering is performed by use of a nebulizer.

8. The method of claim 1 , wherein the polypeptide is the only therapeutic agent administered to the young child.

9. The method of claim 1 , further comprising the step of administering to the young child an additional therapeutic agent.

10. The method of claim 9 , wherein the additional therapeutic agent is a bronchodilator.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2017
From: ALLOSERY, KOEN; DEPLA, ERIK; SARGENTINI, MARIA-LAURA; GERMANI, MASSIMILIANO
To: ABLYNX N.V.
Reel/Frame 043909/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2017
From: HUBER, MARTIN; KOLB, TOBIAS; MULLINGER, BERNHARD; SCHICK, JULIANE
To: VECTURA GMBH
Reel/Frame 043909/0866 →
Priority Claims (1)
EP 14193094 · Nov 13, 2014 · regional
Continuity (4)
Provisional Application 62062469 · Oct 10, 2014
Provisional Application 62067096 · Oct 22, 2014
Provisional Application 62074842 · Nov 4, 2014
Related Publication 20170304566A1 · Oct 26, 2017